On a quiet morning in Las Vegas, Dr. Riana Durrett sipped coffee outside a dispensary on Sahara Avenue, the city’s skyline shimmering behind her—a symbolic intersection of policy and place. Just weeks earlier, on April 23, 2026, the U.S. Department of Justice had reclassified medical cannabis from Schedule I to Schedule III, a seismic shift that could reshape how medicine, business, and science engage with the plant. For Durrett, director of the UNLV Cannabis Policy Institute, the move wasn’t just bureaucratic—it was long-overdue recognition that cannabis belongs in labs and clinics, not locked beside heroin in the nation’s most restrictive drug category.
This reclassification marks the federal government’s first formal step toward legitimizing medical marijuana, Durrett explains. While recreational cannabis remains in Schedule I pending a June 29 administrative hearing by the DEA, the new status for medical use opens critical doors: state-licensed operations can now register with the DEA and operate in compliance with federal law. Most immediately, businesses will be able to escape the punishing grip of IRS tax code 280E, which has for decades barred cannabis companies from deducting ordinary business expenses—forcing many to pay effective tax rates over 70%. With that burden potentially lifted, reinvestment, expansion, and financial stability become real possibilities.
Equally transformative is the impact on research. For years, scientists faced a Kafkaesque maze to study cannabis, limited to sourcing material from only a handful of federally approved suppliers—often plant matter that didn’t reflect what patients actually use. Now, researchers can obtain cannabis directly from state-licensed dispensaries, aligning studies with real-world products. This change arrives alongside the reintroduction of the Higher Education Marijuana Act by Nevada’s Rep. Dina Titus and Minnesota’s Rep. Ilhan Omar, a bipartisan-backed bill designed to fund and expand academic research into cannabis’s medical potential.
The implications ripple far beyond Nevada. Over 30 states already have medical cannabis programs, and the DOJ’s order could catalyze a national framework that harmonizes state and federal law. Patients may gain access to more rigorously tested treatments; entrepreneurs could access banking services long denied; and universities might launch new studies into cannabinoids’ effects on chronic pain, epilepsy, and PTSD.
Still, questions linger. How will the DEA handle registration? What will happen to interstate transport bans? And will recreational cannabis ever follow medical into a lower schedule? The June 29 hearing may offer clues. But for now, the momentum is undeniable—science is no longer waiting in the wings. It’s walking into the dispensary, clipboard in hand, ready to study what millions already use.